波士顿科学下跌超11% 2026年营收预期趋于保守

Core Viewpoint - Boston Scientific's revenue growth forecast for 2026 is conservative, leading to a decline in stock price despite strong Q4 performance [1][2][3] Group 1: Financial Performance - The company reported adjusted earnings per share (EPS) of $0.80 for Q4, exceeding analyst expectations of $0.78 [3] - Revenue for Q4 reached $5.29 billion, slightly above the market forecast of $5.28 billion [3] Group 2: Future Guidance - For 2026, the company expects adjusted EPS to be between $3.43 and $3.49, with a midpoint of $3.46, which is below the analyst average estimate of $3.47 [1][2] - The organic revenue growth forecast for 2026 is projected at 10% to 11%, a decrease from the 15.8% growth rate in 2025 [3] - For Q1 2026, the expected adjusted EPS is between $0.78 and $0.80, compared to the analyst consensus of $0.79 [3] Group 3: Strategic Developments - The company is preparing to complete a $14.5 billion acquisition of Penumbra, announced last month [1][2]